Condition: Plasmodium Vivax Malaria · Sponsor: University of Oxford
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg/kg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg/kg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia.
This description comes directly from the study's public registry record.
Cindy Chu, MD, PhD · +856 (0) 21 250 752 · cindy@tropmedres.ac
Always discuss trial participation with your own doctor first.
| Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia | Siem Reap, Cambodia | Not Yet Recruiting |
| Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU) | Vientiane, Laos | Recruiting |
| Mahidol Vivax Research Unit (MVRU) | Bangkok, Thailand | Not Yet Recruiting |
| Shoklo Malaria Research Unit (SMRU) | Bangkok, Thailand | Not Yet Recruiting |
| Oxford University Clinical Research Unit (OUCRU) | Bình Phước, Vietnam | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04704999